ELCC 2019 | Updates from the PROFILE 1001 study

Alice Tsang Shaw

Alice Tsang Shaw, MD, PhD, of Massachusetts General Hospital Boston, MA, presents updates from the PROFILE 1001 trial (NCT00585195) that looks at crizotinib for advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Dr Shaw describes that both overall and median survival was significantly prolonged than with current therapies. This video was recorded at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.

Share this video